| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
The primary targets of DMT-dI are not traditional biological targets but rather the chemical synthesis of oligonucleotides. As a DMT-protected nucleoside, it is used as a building block in solid-phase oligonucleotide synthesis. The compound is incorporated into oligonucleotide sequences during synthesis and can be converted to other nucleoside analogues through subsequent chemical modifications. It does not have direct enzymatic or receptor targets but serves as a synthetic intermediate.
|
|---|---|
| ln Vitro |
In vitro, DMT-dI functions as a chemical building block rather than a bioactive compound. It is used in the preparation of convertible nucleoside derivatives through standard oligonucleotide synthesis protocols. The DMT (dimethoxytrityl) protecting group allows for selective deprotection and coupling reactions during solid-phase synthesis. The compound itself does not exhibit direct biological activity but enables the synthesis of modified nucleic acids with potential therapeutic applications.
|
| ln Vivo |
In vivo activity of DMT-dI is not applicable, as the compound is a synthetic intermediate used in oligonucleotide synthesis rather than a therapeutic agent. Any in vivo activity would be associated with the final oligonucleotide or nucleoside analog synthesized from this building block. The compound is not intended for direct in vivo administration and is used exclusively for research and synthesis purposes.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not applicable for DMT-dI, as it is a chemical building block rather than a bioactive compound. Quality control assays for this compound typically involve HPLC analysis to verify purity (≥98%) and identity. NMR spectroscopy and mass spectrometry are used to confirm the chemical structure. The compound is also tested for solubility and stability under standard storage conditions.
|
| Cell Assay |
In vitro cellular assays are not applicable for DMT-dI, as it is a chemical building block used in oligonucleotide synthesis rather than a bioactive compound. The compound is not tested in cellular models for biological activity. Instead, its utility is assessed by its performance in oligonucleotide synthesis reactions, including coupling efficiency and purity of the resulting oligonucleotide products.
|
| Animal Protocol |
In vivo animal studies are not applicable for DMT-dI, as it is a chemical building block used in oligonucleotide synthesis rather than a therapeutic agent. The compound is not intended for direct in vivo administration and is used exclusively for research and synthesis purposes. Any in vivo studies would be conducted with the final oligonucleotide or nucleoside analog synthesized from this building block.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of DMT-dI are not relevant, as it is a chemical building block rather than a therapeutic agent. The compound has a molecular weight of 554.59 and a molecular formula of C₃₁H₃₀N₄O₆. It appears as a solid powder with a purity of ≥98%. The compound is stable under recommended storage conditions and is used as a synthetic intermediate in oligonucleotide synthesis.
|
| Toxicity/Toxicokinetics |
The toxicity profile of DMT-dI is not extensively characterized, as it is a chemical building block rather than a therapeutic agent. Standard safety data for handling and use in laboratory settings would apply. The compound is intended for research use only and is not approved for clinical use. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
DMT-dI (CAS 93778-57-5) has a molecular formula of C₃₁H₃₀N₄O₆ and a molecular weight of 554.59. The compound appears as a white to yellow solid with a purity of ≥98%. It is a DMT-protected deoxyinosine derivative used as a building block in oligonucleotide synthesis. The compound is intended for research use only and is not approved for clinical use. It is used in the preparation of convertible nucleoside analogues and modified nucleic acids for research applications.
|
| Molecular Formula |
C31H30N4O6
|
|---|---|
| Molecular Weight |
554.59
|
| Exact Mass |
554.217
|
| CAS # |
93778-57-5
|
| PubChem CID |
136192437
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.206
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
41
|
| Complexity |
875
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
COC1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=C(C=C3)OC)OC[C@@H]4[C@H](C[C@@H](O4)N5C=NC6=C5N=CNC6=O)O
|
| InChi Key |
IYNGMVFRUKBGNM-OYUWMTPXSA-N
|
| InChi Code |
InChI=1S/C31H30N4O6/c1-38-23-12-8-21(9-13-23)31(20-6-4-3-5-7-20,22-10-14-24(39-2)15-11-22)40-17-26-25(36)16-27(41-26)35-19-34-28-29(35)32-18-33-30(28)37/h3-15,18-19,25-27,36H,16-17H2,1-2H3,(H,32,33,37)/t25-,26+,27+/m0/s1
|
| Chemical Name |
9-[(2R,4S,5R)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-4-hydroxyoxolan-2-yl]-1H-purin-6-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 125 mg/mL (225.39 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.75 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.75 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.75 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8031 mL | 9.0157 mL | 18.0313 mL | |
| 5 mM | 0.3606 mL | 1.8031 mL | 3.6063 mL | |
| 10 mM | 0.1803 mL | 0.9016 mL | 1.8031 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
